Case Report: Longitudinal skeletal outcomes during intravenous bisphosphonate therapy in two siblings with SGMS2-associated osteoporosis and calvarial doughnut lesions
- 1Department of Endocrinology and Metabolic Diseases, Polish Mother’s Memorial Hospital – Research Institute
- 2Department of Developmental Age and Adult Endocrinology, Medical University of Lodz
- 3University Pediatric Center, Central Clinical Hospital of the Medical University of Lodz
Abstract
Background: Pathogenic SGMS2 variants are a rare cause of monogenic skeletal fragility, and longitudinal treatment data in affected children are limited.
Case description: We report two sisters carrying the recurrent heterozygous SGMS2 c.148C>T, p.(Arg50Ter) variant who presented with calvarial doughnut lesions, markedly reduced lumbar spine (LS) and total body less head (TBLH) bone mineral density (BMD), and multiple vertebral compression fractures despite no preceding pattern of recurrent peripheral low-trauma fractures. Both received nine cycles of intravenous pamidronate followed by three cycles of zoledronic acid; the switch reflected temporary pamidronate unavailability. During follow-up, LS BMD Z-scores increased from -3.3 to -0.6 and from -3.1 to -0.5, while TBLH BMD Z-scores increased from -2.7 to -0.9 and from -2.3 to -0.7 in Patients 1 and 2, respectively. Neither patient sustained a new low-trauma fracture. Vertebral morphology evolved differently, with reshaping in Patient 1 but persistent vertebral height reduction in Patient 2. Celiac disease was diagnosed in both sisters during treatment, and pubertal development differed between them.
Conclusion: These observations show substantial longitudinal increases in BMD Z-scores and the absence of new low-trauma fractures during intravenous bisphosphonate therapy, while vertebral morphological outcomes differed between the siblings. Growth, pubertal maturation, and treatment of concomitant celiac disease may also have influenced bone accrual; longitudinal assessment should therefore integrate fractures, vertebral morphology, growth, maturation, and DXA.
Related
- Artificial Intelligence‐Driven Precision Bisphosphonate Therapy in Osteoporosis: Mechanisms, Clinical Applications, Risks, and Future Directions
- Acute Enlargement of a Frontal Calvarial Lesion in Polyostotic Fibrous Dysplasia Associated with McCune–Albright Syndrome: A Case Report
- Longitudinal pre-diagnostic blood samples predict osteoporosis risk
- Beyond static frailty: longitudinal trajectories, nonlinear associations, and muscle strength mediation in osteoporosis risk.
- Socioeconomic status and incident osteoporosis risk in older adults: a longitudinal analysis of the English longitudinal study of ageing and the health and retirement study
BibTeX
@article{lupinska2026case,
title = {{Case Report: Longitudinal skeletal outcomes during intravenous bisphosphonate therapy in two siblings with SGMS2-associated osteoporosis and calvarial doughnut lesions}},
author = {Anna Łupińska and Sara Aszkiełowicz and Danuta Chlebna-Sokół and Renata Stawerska and Arkadiusz Zygmunt and Izabela Michałus},
journal = {Frontiers in Endocrinology},
year = {2026},
month = nov,
doi = {10.3389/fendo.2026.1995754},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1995754/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case Report: Longitudinal skeletal outcomes during intravenous bisphosphonate therapy in two siblings with SGMS2-associated osteoporosis and calvarial doughnut lesions
AU - Anna Łupińska
AU - Sara Aszkiełowicz
AU - Danuta Chlebna-Sokół
AU - Renata Stawerska
AU - Arkadiusz Zygmunt
AU - Izabela Michałus
PY - 2026
DA - 2026/11/09
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1995754
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1995754/full
AB - Background: Pathogenic SGMS2 variants are a rare cause of monogenic skeletal fragility, and longitudinal treatment data in affected children are limited. Case description: We report two sisters carrying the recurrent heterozygous SGMS2 c.148C>T, p.(Arg50Ter) variant who presented with calvarial doughnut lesions, markedly reduced lumbar spine (LS) and total body less head (TBLH) bone mineral density (BMD), and multiple vertebral compression fractures despite no preceding pattern of recurrent peripheral low-trauma fractures. Both received nine cycles of intravenous pamidronate followed by three cycles of zoledronic acid; the switch reflected temporary pamidronate unavailability. During follow-up, LS BMD Z-scores increased from -3.3 to -0.6 and from -3.1 to -0.5, while TBLH BMD Z-scores increased from -2.7 to -0.9 and from -2.3 to -0.7 in Patients 1 and 2, respectively. Neither patient sustained a new low-trauma fracture. Vertebral morphology evolved differently, with reshaping in Patient 1 but persistent vertebral height reduction in Patient 2. Celiac disease was diagnosed in both sisters during treatment, and pubertal development differed between them. Conclusion: These observations show substantial longitudinal increases in BMD Z-scores and the absence of new low-trauma fractures during intravenous bisphosphonate therapy, while vertebral morphological outcomes differed between the siblings. Growth, pubertal maturation, and treatment of concomitant celiac disease may also have influenced bone accrual; longitudinal assessment should therefore integrate fractures, vertebral morphology, growth, maturation, and DXA.
SN - 1664-2392
ER -